• Oxford Gene Technology Ltd., of Oxford, UK, filed a lawsuit in the English High Court of Justice to revoke Affymetrix Inc.’s two UK patents relating to DNA microarrays. OGT maintains Affymetrix’s UK and European patents are unjustifiably broad and could restrain the development of array technology. It is the fourth action to date taken by OGT against Affymetrix, of Santa Clara, Calif.

• PathoGenesis Corp., of Seattle, said the UK Department of Health has licensed TOBI 300 mg/5mL Nebuliser Solution for the long-term management of chronic pulmonary infection due to Pseudomanas aeruginosa in cystic fibrosis patients ages 6 or older. TOBI has been sold in the U.S. since 1998.

• Quark Biotech Inc., of Pleasanton, Calif., received a milestone payment from Mitsubishi-Tokyo Pharmaceuticals Inc., of Tokyo, after Mitsubishi decided to screen for a small-molecule lead compound and start development of a candidate based on a new gene implicated in neuron death. The two companies started their collaboration in 1995.

• Questcor Pharmaceuticals Inc., of Hayward, Calif., signed a licensing agreement with Laboratorios Silesia SA, of Chile, for marketing Emitasol (metaclopramide nasal spray) in Chile. Questcor received a small up-front payment and will receive royalties on net sales. Emitasol is an intranasally administered product intended for treating delayed onset nausea and vomiting in cancer chemotherapy patients, as well as treating diabetic gastroparesis.

• Sequenom Inc., of San Diego, installed a MassArray system at the National Cancer Institute that will be used for the analysis of variations, or single nucleotide polymorphisms, that occur in genes involved with cancer and other diseases. MassArray combines Sequenom’s proprietary enzymology and bioinformatics in a miniaturized chip-based format with mass spectrometry technology.